Correlation of endocrine profiles with bleeding patterns during use of Nestorone® contraceptive implants

Human Reproduction

Volumn 14, Issue 12, 1999, Pages 3013-3017

  Faúndes, Anibal ^a   Alvarez, Francisco ^b   Brache, Vivian ^b   Cochón, Leila ^b   Tejada, Ana Sofia ^b   Moo Young, Alfred ^c  

^a Ctro Pesq Doencas Materno I   (Brazil)

^b PROFAMILIA   (Dominican Republic)

^c POPULATION COUNCIL   (United States)

Author keywords

Bleeding patterns; Contraceptive implants; Nestorone ; Oestradiol; Progesterone

Indexed keywords

ELCOMETRINE; ESTRADIOL; PROGESTERONE;

ADULT; AMENORRHEA; ARTICLE; BLEEDING; BLOOD SAMPLING; CONTRACEPTION; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; IMPLANT; MENSTRUAL CYCLE; NORMAL HUMAN; PROGESTERONE BLOOD LEVEL; TIME;

NES;

EID: 0345440055     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/14.12.3013     Document Type: Article

References (22)

1. Alvarez-Sanchez, F., Brache, V. and Faúndes, A. (1993) Recent experience with and future directions of contraceptive implants and injectable contraceptives. Curr. Opin. Obstet. Gynecol., 5, 805-814.
2. Alvarez-Sanchez, F., Brache, V., Thevenin, F. et al. (1996) Hormonal treatment for bleeding irregularities in Norplant implant users. Am. J. Obstet. Gynecol., 174, 919-922.
3. Archer, D.F., Philput, C.A. and Weber, M.E. (1996) Management of irregular uterine bleeding and spotting associated with Norplant®. Hum. Reprod., 11, 24-30.
4. Bassol, S., Garza-Flores, J., Cravioto, M.C. et al. (1984) Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses. Fertil. Steril., 42, 216-222.
5. Darney, P.D., Taylor, R.N., Klaisle, C. et al. (1996) Serum concentrations of oestradiol, progesterone and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant® implant users. Contraception, 53, 97-100.
6. Díaz, S., Croxatto, H.B., Pavez, M. et al. (1990) Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception, 42, 97-109.
7. Díaz, S., Schiappacasse, V., Pavez, M. et al. (1995) Clinical trial with Nestorone subdermal contraceptive implants. Contraception, 51, 33-38.
8. Faúndes, A., Alvarez-Sanchez, F., Brache, V. et al. (1991) Hormonal changes associated with bleeding during low dose progestogen contraception delivered by Norplant subdermal implants. Adv. Contracept., 7, 85-94.
9. Faúndes, A., Alvarez-Sanchez, F., Brache, V. et al. (1998) Endometrial thickness and oestradiol concentration in women with bleeding complaints during use of Norplant® implants. Hum. Reprod., 13, 188-191.
10. Fraser, I.S., Hickey, M. and Song J. (1996) A comparison of mechanisms underlying disturbances of bleeding caused by spontaneous dysfunctional uterine bleeding or hormonal contraception. Hum. Reprod., 11, 165-178.
11. Goebelsmann, U., Stanczyk, F.Z., Brenner, P.F. et al. (1979) Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, oestradiol and progesterone. Contraception, 19, 283-313.
12. Goodger, A.M., Roger, P.A.W. and Affandi, B. (1994) Endometrial endothelial cell proliferation in long-term users of subdermal levonorgestrel. Hum. Reprod., 9, 1647-1651.
13. Hickey, M., Dwarte, D. and Fraser, I.S. (1998) Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum. Reprod., 13, 3190-3198.
14. Kim-Bjorklund, T., Landgren, B.M. and Johanisson, E. (1991) Morphometric studies of the endometrium, the fallopian tube and the corpus luteum during contraception with the 300 μg norethisterone (NET) minipill. Contraception, 43, 459-474.
15. Ladipo, O. and Coutinho, E.M. (1994) Contraceptive implants. Curr. Opin. Obstet. Gynecol., 6, 564-569.
16. Lahteenmaki, P.L.A., Díaz, S., Miranda, P. et al. (1990) Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435. Contraception, 42, 555-562.
17. Landgren, B.M., Oriowo, M.A. and Diczfalusy, E. (1981) Pharmacokinetic and pharmacodynamic studies with vaginal devices releasing norethisterone at a constant, near zero order. Contraception, 24, 29-44.
18. Landgren, B.M., Johanisson, E., Masironi, B. et al. (1982) Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. Contraception, 26, 567-585.
19. Landgren, B.M., Aedo, A.R., Johanisson, E. et al. (1994) Pharmacokinetic and pharmacodynamic effects of vaginal rings releasing levonorgestrel at a rate of 27 μg/24 hours: a pilot study. Contraception, 49, 139-150.
20. Olsson, S.E., Bakos, O., Lindgren, P.G. et al. (1990) Ovarian function during use of subdermal implants releasing low doses of levonorgestrel. Br. J. Fam. Plann., 16, 88-93.
21. Rogers, P.A.W., Au, S.L. and Affandi, B. (1993) Endometrial vascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum. Reprod., 8, 1396-1404.
22. Shaaban, M.M., Segal, S., Salem, H.T. et al. (1993) Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal concentrations. Fertil. Steril., 59, 998-1002.